Accueil   Diary - News   All news SIGNIA THERAPEUTICS OBTAINS EUROPEAN FUNDING TO ACCELERATE THE DEVELOPMENT OF ITS SIGNATURA® PLATFORM

SIGNIA THERAPEUTICS OBTAINS EUROPEAN FUNDING TO ACCELERATE THE DEVELOPMENT OF ITS SIGNATURA® PLATFORM

 

 

 

Signia Therapeutics announced today that it has received a grant of € 2.38 million from the European Commission as part of the "EIC Accelerator Phase 2” (SME Instrument) call for projects for the development of its SIGNATURA® platform dedicated to the repositioning of drugs.

 


The SIGNATURA® platform has already enabled the preclinical identification and validation of several drugs for their repositioning in the treatment of respiratory infections, in particular in severe forms of influenza. The European funding "H2020 EIC Accelerator" will significantly accelerate the development of the SIGNATURA® platform for the validation of new generation antiviral molecules.

 

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree